| Prev Close | 158.59 |
| Day Low/High | 157.28 / 161.15 |
| 52 Wk Low/High | 142.81 / 256.80 |
| Avg Volume | 3.14M |
| Exchange | NYSE |
| Shares Outstanding | 345.73M |
| Market Cap | 54.83B |
| EPS | -13.20 |
| P/E Ratio | N/A |
| Div & Yield | 2.88 (1.70%) |
-- Phase 3 Oral CGRP Results for Ubrogepant Accepted as Late Breaker Emerging Science Presentation --
Jim discusses earnings from Nucor and Danaher, recent headlines about Apple, Amazon, Allergan, and more!
I don't understand the fundamentals but I find the chart interesting.
How do you get a stock moving? Jim Cramer says the answer is to invest in technology.
Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.
Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!
The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.
The drug company generates about 60% of revenue outside the U.S.
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.
The pharmaceutical firm will conduct its investor day in New York City on April 11.
McKesson and other drug distributors are having a difficult time steering clear of controversy, with the latest blow a lawsuit alleging McKesson has violated the False Claims Act.
Aegon has successfully priced USD 800 million Tier 2 subordinated debt securities, first callable on April 11, 2028, and maturing on April 11, 2048.
Today, Aegon has successfully completed the sale of Aegon Ireland plc to Athora Holding Ltd.
We have long been fans of UNH as the company is a strong defensive name.
We will sell more AGN, consistent with our Three rating, and continue to scale into GS.
Fears of a trade war and a Fed rate hike marked a volatile week.
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
We are not jumping up and down to put capital to work, but when we see things we like, we will buy them in increments.
We'll take advantage of this opportunity to buy on weakness with our healthy cash position.
President Trump made a long-awaited announcement of his administration's opioid plan in a New Hampshire speech that was part policy roll out and part political rally.
Notable weakness is coming from the FANG leadership group, which is being weighed down by heavy losses in Facebook.
White House gets new economic adviser.
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
We still believe that the overhang that limited Broadcom stock's lift over the last few months has been removed.
Trump signs tariffs...markets recover
